U.S. markets closed

Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)

NSE - NSE Real Time Price. Currency in INR
Add to watchlist
465.75+9.40 (+2.06%)
At close: 3:30PM IST
Show:
Income Statement
Balance Sheet
Cash Flow
Annual
Premium required to access quarterly data
Quarterly
Subscribe to Premium to download historical data

Income Statement

All numbers in thousands
Get access to 40+ years of historical data with Yahoo Finance Premium.Learn more
Breakdown
ttm
3/31/2020
3/31/2019
3/31/2018
3/31/2017
Total Revenue
320,483,900
328,375,000
290,659,100
264,885,100
313,081,400
Cost of Revenue
99,830,800
104,712,700
92,387,600
88,257,700
94,247,200
Gross Profit
220,653,100
223,662,300
198,271,500
176,627,400
218,834,200
Operating Expense
173,325,500
174,308,000
151,024,800
135,757,500
133,342,400
Operating Income
47,327,600
49,354,300
47,246,700
40,869,900
85,491,800
Net Non Operating Interest Income Expense
1,161,800
640,700
1,439,600
682,500
408,400
Pretax Income
11,782,500
50,095,900
38,102,000
34,789,800
90,478,700
Tax Provision
9,226,500
8,228,000
6,008,800
8,451,900
12,115,700
Net Income Common Stockholders
7,218,500
37,649,300
26,654,200
21,615,500
69,643,700
Diluted NI Available to Com Stockholders
7,218,500
37,649,300
26,654,200
21,615,500
69,643,700
Basic EPS
-
0.0157
0.0111
0.009
0.029
Diluted EPS
-
0.0157
0.0111
0.009
0.029
Basic Average Shares
-
2,399,335
2,399,327
2,399,297
2,403,320
Diluted Average Shares
-
2,399,335
2,399,330
2,399,362
2,403,523
Rent Expense Supplemental
-
362,400
1,327,600
1,120,800
1,237,800
Total Expenses
273,156,300
279,020,700
243,412,400
224,015,200
227,589,600
Net Income from Continuing & Discontinued Operation
7,218,500
37,649,300
26,654,200
21,615,500
69,643,700
Normalized Income
34,364,360
39,009,491
35,963,603
27,131,350
69,326,104
Interest Income
-
3,546,200
6,692,100
5,197,600
3,711,700
Interest Expense
2,384,400
2,905,500
5,252,500
4,515,100
3,303,300
Net Interest Income
1,161,800
640,700
1,439,600
682,500
408,400
EBIT
14,166,900
53,001,400
43,354,500
39,304,900
93,782,000
EBITDA
35,082,600
-
-
-
-
Reconciled Cost of Revenue
99,830,800
104,712,700
92,387,600
88,257,700
94,247,200
Reconciled Depreciation
20,915,700
20,527,800
17,532,500
14,998,400
12,647,500
Net Income from Continuing Operation Net Minority Interest
7,218,500
37,649,300
26,654,200
21,615,500
69,643,700
Total Unusual Items Excluding Goodwill
-38,779,800
-1,627,500
-11,052,400
-7,285,900
366,700
Total Unusual Items
-38,779,800
-1,627,500
-11,052,400
-7,285,900
366,700
Normalized EBITDA
73,862,400
75,156,700
71,939,400
61,589,200
106,062,800
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-11,633,940
-267,309
-1,742,997
-1,770,050
49,104